Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials

Pharmaceutical Research

Volumn 29, Issue 12, 2012, Pages 3475-3485

  Akash, Muhammad Sajid Hamid ^a,b   Rehman, Kanwal ^a   Li, Ni ^a   Gao, Jian Qing ^a   Sun, Hongying ^a   Chen, Shuqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

Akaike information criterion; Controlled release; In vitro study; In vivo study; Interleukin 1 receptor antagonist; Pharmacokinetics

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; POLOXAMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; CONCENTRATION (PARAMETERS); DISSOLUTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG STABILITY; GEL; HEAT SENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; LOW TEMPERATURE PROCEDURES; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIRHEUMATIC AGENTS; DELAYED-ACTION PREPARATIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GELS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; POLOXAMER; PROTEIN STABILITY; RATS; RATS, WISTAR; TEMPERATURE;

EID: 84872064405     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0843-0     Document Type: Article

References (50)

1. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics. 1992;13:654-7.
2. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55. (Pubitemid 28183358)
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Rev Immunol. 2011;11:98-107.
4. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005;48:1038-50. (Pubitemid 40909636)
5. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269:16-28.
6. Dayer JM, Feige U, Edwards CK, Burger D. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol. 2001;13:170-6. (Pubitemid 32430067)
7. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis. 1999;58:196-8.
8. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 1996;39:1092-101. (Pubitemid 26240220)
9. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JE, Seifert B, et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1417-526.
10. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6:158-66.
11. Cawthorne C, Prenant C, Smigova A, Julyan P, Maroy R, Herholz K, et al. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [18F]-IL1RA and PET imaging in rats. Br J Pharmacol. 2011;162:659-72.
12. Holt LJ, Basran A, Jones K, Chorlton J, Jespers SL, Brewis ND, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008;21:283-8.
13. Lavi G, Dinarello CA, Apte RN, Cohen S. Sustained release of IL-1Ra from biodegradable microspheres prolongs its IL-1-neutralizing effects. Israel J Chem. 2005;45:457-64. (Pubitemid 41659581)
14. Pichika R, Betre H, Setton LA, An HS, Masuda K. Bioactivity of IL-1 receptor antagonist (IL-1Ra) and a related fusion protein in inhibiting IL-1-mediated effects in human intervertebral disc cells. Trans Orthop Res Soc. 2006;52.
15. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S. Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release. 2007;123:123-30. (Pubitemid 47562137)
16. Shamji MF, Betre H, Kraus VB, Chen J, Chilkoti A, Pichika R, et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local anti-inflammatory therapeutic. Arthritis Rheum. 2007;56:3650-61. (Pubitemid 350100699)
17. Kim DH, Smith JT, Chilkoti A, Reichert WM. The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes. Biomaterials. 2007;28:3369-77. (Pubitemid 46726629)
18. Dai SF, Shen Q, Chen S. Inhomogeneous expression of fusion protein HSA/IL-1Ra pichia pastoris. J Zhejiang Univ (Medical Sci). 2008;37:134-8.
19. Jun. JB, Kim JK, Kim TH, Na Y, Choi CH, Kim YH. Inhibition of the IL-1β-induced expression of matrix metalloproteinases by controlled release of IL-1 receptor antagonist using injectable and thermo-reversible gels in human osteoarthritis chondrocytes. J Rheum Dis. 2011;18:85-93.
20. Akash MSH, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci. 2012;10:1647-58.
21. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm. 1999;184:189-98. (Pubitemid 29317652)
22. Katakam M, Bell LN, Banga AK. Effect of surfactants on the physical stability of rhGH. J Pharm Sci. 1995;84:13-716.
23. Stratton LP, Dong A, Manning MC, Carpenter JF. Drug delivery matrix containing native protein precipitates suspended in a polomaxamer gel. J Pharm Sci. 1997;86:1006-10. (Pubitemid 27382901)
24. Liu Y, Lu WL, Wang JC, Zhang X, Zhang H, Wang XQ, et al. Controlled delivery of recombinant hirudin based on thermosensitive pluronic® F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization. J Control Release. 2007;117:387-95. (Pubitemid 46216584)
25. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res. 1992;9:425-34.
26. Soga O, Van Nostrum CF, Fens M, Fijcken CJF, Schiffelers RM, Storm G, et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release. 2005;103:341-53. (Pubitemid 40342534)
27. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a thermosensitive Chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin. Open Drug Delivery J. 2008;2:61-70.
28. Hyun H, Kim YH, Song IB, Lee JW, Kim MS, Khang G, et al. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier. Biomarcomolecules. 2007;78:1093-100. (Pubitemid 46672685)
29. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release. 2002;85:73-81. (Pubitemid 35449455)
30. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263-71.
31. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control. 1974;19:716-23.
32. Khan SA, Ahmad M, Murtaza G, Shehnaz G, Aamir MN, Rasool F. Design of nimesulide-chitosan microparticles by pH change coacervation. Lat Am J Pharmacy. 2011;30:1260-6.
33. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110-1.
34. Wagner JG, Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 1963;52:610-1.
35. Wannachaiyasit S, Phaechamud T. Development of chlorhexidine thermosensitive gels as a mouth antiseptic. J Metals Mater Miner. 2010;20:165-8.
36. Nie S, Hsiao WW, Pan W, Yang Z. Thermosensitive pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomed. 2011;6:151-61.
37. Bonacucina G, Spina M, Misici-Falzi M, Cespi M, Pucciarelli S, Angeletti M, et al. Effect of hydroxypropyl β-cyclodextrin on the self-assembling and thermogelation properties of poloxamer 407. Eur J Pharm Sci. 2007;32:115-22. (Pubitemid 47285720)
38. Costa FO, Sousa JJ, Pais AA, Formosinho SJ. Comparison of dissolution profiles of Ibuprofen pellets. J Control Release. 2003;89:199-212. (Pubitemid 36507015)
39. Veyries ML, Couarraze G, Geiger S. Controlled release of vancomycin from poloxamer 407 gels. Int J Pharm. 1999;192:183-93. (Pubitemid 29531552)
40. Pandit NK, Wang D. Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels. Int J Pharm. 1998;167:183-9. (Pubitemid 28341520)
41. Reza MS, Quadir MA, Haider SS. Development of theophylline sustained release dosage form based on kollidon SR. Pak J Pharm Sci. 2002;15:63-70.
42. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS Prarm Sci Tech. 2006;7:E1-9.
43. Akash MSH, Rehman K, Rasool F, Sethi A, Abrar MA, Irshad A, et al. Alternate therapy of Type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae). J Med Plants Res. 2011;5:6885-9.
44. Homo-Delarche F, Calderari S, Irminger JC, Gangnerau MN, Coulaud J, Rickenbach K, et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes. 2006;55:1625-33. (Pubitemid 44324114)
45. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000;343:732-4.
46. Banerjee PS, Hosny EA, Robinson JR. Parenteral delivery of peptides and protein drugs. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker; 1991. p. 487-543.
47. Lu G, Jun. HW. Diffusion studies of methotrexate in Carbopol and Poloxamer gels. Int J Pharm. 1998;160:1-9. (Pubitemid 28059924)
48. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353-60.
49. McIntyre KW, Stepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM, Kaffka KL, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991;173:931-9.
50. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from a and β cell compensation to dysfunction. Arch Physiol Biochem. 2009;115:240-7.